A Phase 1 interventional study of Naproxen Sodium ER (BAY117031), 20% HPMC and Naproxen Sodium ER (BAY117031), 30% HPMC in Pain, sponsored by Bayer. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-09-15.
Sponsored by Bayer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing naproxen in Pain — 1 open to participants now, 2 under way, none of them phase 3. Naproxen · Pain.
Among the 25 studies testing naproxen in Pain, this one is the 21st largest by enrollment, is the only one that started in 2007, is one of 5 in phase 1, and was the 11th registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →1 of the 25 studies testing naproxen in Pain is open now, in 1 country. Recruiting first, the newest first:
American University of Beirut Medical Center · Sites in Lebanon
Ages 18+
By country, each count listing its studies:
Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →
Of the 928 Pain studies recruiting now, 384 (41%) set no upper age limit and 432 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 100 across the 25 interventional studies. Of the 22 that completed or were terminated, 13 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 25 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
14 studies in Pain by Bayer: none open now, none under way, none of them phase 3. Of 14 finished, 5 (36%) have results posted.
Among the 14 studies in Pain by Bayer, this one is the 11th largest by enrollment, is the only one that started in 2007, is one of 8 in phase 1, and was the 6th registered.
Bayer’s Pain studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing naproxen in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 14 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Bioequivalence trial in healthy adult subjects to determine the bioavailability of 3 different sustained release formulations of naproxen 660 mg relative to the established commercial Aleve 220 mg tablet.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve (Naproxen sodium) 220 mg tablet
Drug: Naproxen Sodium ER (BAY117031), 20% HPMC
Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve 220 mg tablet
Drug: Naproxen Sodium ER (BAY117031), 30% HPMC
Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve 220 mg tablet
Drug: Naproxen Sodium ER (BAY117031), 40% HPMC
Bioequivalence in healthy adult subjects in a fasted state
Drug: Aleve (Naproxen Sodium, BAY117031)
1 tablet 660 mg administered orally once daily
1 tablet 660 mg administered orally once daily
1 tablet 660 mg administered orally once daily
1 tablet 220 mg administered orally three times daily
Cmax (maximum plasma concentration) for naproxen sodium
Time frame: Days 0, 1, 2, and 3
AUC0-24 (partial area under the curve ) for naproxen sodium
Time frame: Days 0, 1, 2, and 3
AUC0-t (areas under the curve ) for naproxen sodium
Time frame: Days 0, 1, 2, and 3
AUC0-∞ (area under the curve) for naproxen sodium
Time frame: Days 0, 1, 2, and 3
Tmax (The first time point where Cmax is reached) for naproxen sodium
Time frame: Days 0, 1, 2, and 3
AUC0-8 (partial area under the curve) for naproxen sodium
Time frame: Days 0, 1, 2, and 3
AUC8-16 (partial area under the curve ) for naproxen sodium
Time frame: Days 0, 1, 2, and 3
AUC16-24 (partial area under the curve) for naproxen sodium
Time frame: Days 0, 1, 2, and 3
λz (terminal elimination rate constant)
Time frame: Days 0, 1, 2, and 3
t1/2 (terminal half life)
Time frame: Days 0, 1, 2, and 3
Adverse events (AEs) collection
Time frame: up to 50 days
Serious adverse events (SAEs) collection
Time frame: up to 50 days
Vital signs: sitting blood pressure
Time frame: up to 50 days
Vital signs: repiratory rate
Time frame: up to 50 days
Vital signs : pulse rate
Time frame: up to 50 days
Clinical Laboratory data
Blood and urine samples were collected according to standard medical guidelines at the Screening Visit. In addition, hematology and chemistry were obtained at the end of the study (EOS).
Time frame: up to 50 days
Physical examination findings
Brief physical examination, including height, weight and BMI, was performed at the Screening Visit and at EOS
Time frame: up to 50 days
No study locations are listed for this record.
The record gives a start of Mar 2007, a primary completion of May 2007 and a completion of May 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naproxen